Belantamab mafodotin (12 weeks)

Phase 2

GSK plc (GSK)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

GSKPhase 2$100.5B

Belantamab mafodotin (12 weeks) Phase 2 Est. Readout

Belantamab mafodotin (12 weeks)• AL Amyloidosis37

Mar 2027~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in AL Amyloidosis

View Full Landscape

Drug Information

Target Indication

AL Amyloidosis

Clinical Trial

NCT05145816

Last updated: 11/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Combined Hepatitis A and B vaccinePhase 3

Hepatitis B

GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3

Infections, Meningococcal

62.5/25mcgPhase 3

Pulmonary Disease, Chronic Obstructive

FluoridePhase 3

Dental Caries

Haemophilus influenzae type b- and meningococcal (vaccine)Phase 3

Haemophilus Influenzae Type b

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts